Leap Net Working Capital from 2010 to 2024

LPTX Stock  USD 3.30  0.14  4.43%   
Leap Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital will likely drop to about 46.5 M in 2024. During the period from 2010 to 2024, Leap Therapeutics Net Working Capital regression line of annual values had significance of  0.03 and arithmetic mean of  32,873,922. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
58.9 M
Current Value
46.5 M
Quarterly Volatility
26.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Leap Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Leap Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 336.9 K, Interest Expense of 4.8 K or Selling General Administrative of 8.7 M, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0025 or PTB Ratio of 1.41. Leap financial statements analysis is a perfect complement when working with Leap Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Leap Therapeutics Correlation against competitors.
For more information on how to buy Leap Stock please use our How to Invest in Leap Therapeutics guide.

Latest Leap Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Leap Therapeutics over the last few years. It is Leap Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Leap Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Leap Net Working Capital Regression Statistics

Arithmetic Mean32,873,922
Coefficient Of Variation81.04
Mean Deviation19,935,096
Median21,575,000
Standard Deviation26,642,145
Sample Variance709.8T
Range111.1M
R-Value0.55
Mean Square Error530.4T
R-Squared0.31
Significance0.03
Slope3,295,817
Total Sum of Squares9937.3T

Leap Net Working Capital History

202446.5 M
202358.9 M
202256.7 M
2021106.9 M
202044.9 M
2019-4.2 M
201810.9 M

About Leap Therapeutics Financial Statements

Leap Therapeutics investors use historical fundamental indicators, such as Leap Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Leap Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital58.9 M46.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Leap Stock Analysis

When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.